Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 1998

View Archived Issues

Amylin announces results from pramlintide phase III studies

UCB acquires CytoMed assets and development pipeline

AERx Diabetes Management System enters phase II trials

ICN obtains rights to Senetek skincare cosmeceutical

Senetek licenses autoinjectable drug delivery system to ICN

Antiprogestin with potential as an oral postcoital contraceptive in women

Prostaglandin analogues attenuate ischemic liver damage in canine model

Selective ETA or mixed ETA/ETB antagonist for CHF?

Positive efficacy and safety results reported for IDEC-Y2B8/Rituxan in NHL

FDA clears first test for CMV DNA

Phase III study evaluates efficacy of tacrolimus in bone marrow transplantation

GlycoDesign and NRC agreement represents new approach to antibiotics

(+)-Enantiomer of known compound acts as potent, selective NMDA receptor antagonist

Novel class of vitamin D derivatives for metabolic bone diseases, psoriasis

Calpain inhibitors jointly developed by SKB and Cephalon

Difluoronucleoside antineoplastic and antiherpesvirus agents from Lilly

Astra's new antiasthmatic, antirhinitic agents

Thiocarbamic acid derivatives as inhibitors of squalene epoxidase

Positive initial clinical findings reported for first-generation GVAX vaccine for melanoma

AChE inhibition does not contribute to the neuroprotective effects of anseculin in vivo

Paralyzed mice regain the ability to walk following treatment with CM-101

Novel class of microtubule-destabilizing agents synthesized and evaluated at Kansas State

Addition of Remune increases efficacy of HAART in HIV-positive patients

CEA-Scan accurately detects breast cancer with low rate of false-positive results

European approval for Roche's sale of DePuy

CollaGenex seeks E.U.-wide approval of Periostat

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...